ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Brain and Development
Volume 27, Issue 4, June 2005, Pages 286-290
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (292 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.braindev.2004.08.005    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2004 Elsevier B.V. All rights reserved.

Original article

Zonisamide for West syndrome: a comparison of clinical responses among different titration rate

Shigeru Yanagakia, b, Hirokazu Ogunia, Corresponding Author Contact Information, E-mail The Corresponding Author, Keisuke Yoshiia, Kitami Hayashia, Kaoru Imaia, Makoto Funatsukaa and Makiko Osawaa

aDepartment of Pediatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan bTakaido Child Clinic, Suginami-ku, Tokyo, Japan

Received 18 May 2004; 
revised 22 July 2004; 
accepted 23 August 2004. 
Available online 17 November 2004.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

We administered zonisamide (ZNS) to patients with West syndrome in different titration protocols and compared their short-term therapeutic effects. We designed three protocols to raise the serum ZNS concentration (SZC): (1) increase the dose in three steps, from 3 to 10 mg/kg every 3 days, (2) increase the dose from 5 to 10 mg/kg over 3–7 days, and (3) start with 10 mg/kg and maintain this dosage for 2 weeks. The subjects were 23 infants with West syndrome, 8 of whom comprised the 1st group, 5 the 2nd group, and the remaining 10, the 3rd group. As a result, excellent and good effects were obtained in a total of seven patients (30.4%) and one patient, respectively (1/8 in the 1st step-up group, 3/5 in the 2nd step-up group, and 4/10 in the 3rd group). The maximum SZC was higher in the excellent and good effect groups (n=8; 32.0±8.0 μg/ml) than in the ineffective group (n=15; 22.4±8.2 μg/ml) (P<0.05). The period of time required for cessation of spasms appeared shorter in the 3rd group (n=4; mean=5.7 days) than in the 1st and 2nd groups (n=4; mean=10.3 days). There were few side effects except for transient hyperthermia and gastrointestinal symptoms. Our new protocol of starting with 10 mg/kg of ZNS can be introduced safely and make a therapeutic judgment feasible within 2 weeks.

Keywords: West syndrome; Zonisamide; Fast titration; Pharmacokinetics; Treatment protocol

Article Outline

1. Introduction
2. Subjects and methods
2.1. Statistical analysis
3. Results
3.1. Side effects
4. Discussions
Acknowledgements
References


Brain and Development
Volume 27, Issue 4, June 2005, Pages 286-290
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.